13.79

2.22% 0.27

Relay Therapeutics Inc (RLAY)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt RLAY? Forum Prognose

Schlusskurs vom Vortag:

$13.52

Offen:

$13.91

24-Stunden-Volumen:

473.54K

Relative Volume:

0.13

Marktkapitalisierung:

$3.01B

Einnahmen:

$15.36M

Nettoeinkommen (Verlust:

$-276.48M

KGV:

-8.5498

EPS:

-1.6129

Netto-Cashflow:

$-235.87M

1W Leistung:

-3.09%

1M Leistung:

+8.31%

6M Leistung:

+81.13%

1J Leistung:

+311.31%

1-Tages-Spanne:

$13.51

$13.94

1-Wochen-Bereich:

$12.93

$17.47

52-Wochen-Spanne:

$2.98

$17.47

Relay Therapeutics Inc Stock (RLAY) Company Profile

Firmenname

Relay Therapeutics Inc

Sektor

Healthcare (1105)

Branche

Biotechnology (614)

Telefon

617-370-8837

Adresse

60 HAMPSHIRE STREET, CAMBRIDGE

Mitarbeiter

192

Twitter

Nächster Verdiensttermin

2026-05-05

Neueste SEC-Einreichungen

RLAY's Discussions on Twitter

Compare RLAY vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
RLAY Relay Therapeutics Inc	13.79	2.95B	15.36M	-276.48M	-235.87M	-1.6129
VRTX Vertex Pharmaceuticals Inc	445.00	113.41B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	620.51	66.62B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	888.23	55.43B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	286.84	40.46B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	149.53	31.73B	742.00K	-1.37B	-1.07B	-7.0731

Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-26	Hochstufung	Oppenheimer	Perform → Outperform
2025-12-12	Hochstufung	Wells Fargo	Equal Weight → Overweight
2025-09-04	Fortgesetzt	Guggenheim	Buy
2025-04-17	Eingeleitet	Wells Fargo	Equal Weight
2024-09-10	Fortgesetzt	Goldman	Buy
2024-09-10	Hochstufung	Jefferies	Hold → Buy
2024-09-10	Herabstufung	Oppenheimer	Outperform → Perform
2024-05-10	Hochstufung	Barclays	Equal Weight → Overweight
2023-04-20	Hochstufung	Jefferies	Underperform → Hold
2023-04-19	Hochstufung	Raymond James	Outperform → Strong Buy
2023-04-13	Eingeleitet	Raymond James	Outperform
2023-02-03	Eingeleitet	Oppenheimer	Outperform
2022-09-30	Eingeleitet	Barclays	Equal Weight
2022-09-02	Eingeleitet	Stifel	Buy
2022-06-06	Eingeleitet	Jefferies	Underperform
2022-02-01	Eingeleitet	Berenberg	Buy
2021-07-21	Eingeleitet	BofA Securities	Buy
2020-12-15	Bestätigt	H.C. Wainwright	Buy
2020-12-08	Eingeleitet	JMP Securities	Mkt Outperform
2020-11-05	Eingeleitet	H.C. Wainwright	Buy
2020-08-10	Eingeleitet	Cowen	Outperform
2020-08-10	Eingeleitet	Goldman	Buy
2020-08-10	Eingeleitet	Guggenheim	Buy
2020-08-10	Eingeleitet	JP Morgan	Neutral

Alle ansehen

Relay Therapeutics Inc Aktie (RLAY) Neueste Nachrichten

Jun 05, 2026

RLAY Technical Analysis | Trend, Signals & Chart Patterns | RELAY THERAPEUTICS INC (NASDAQ:RLAY) - ChartMill

Jun 05, 2026

Jun 04, 2026

RLAY stock lights up on vascular anomalies treatment data boost – 60% of patients show sharp reduction in lesion volume - MSN

Jun 04, 2026

RLAY Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Jun 04, 2026

Jun 03, 2026

Relay Therapeutics Hits Day High with 10.1% Surge in Strong Intraday Performance - Markets Mojo

Jun 03, 2026

Analysts Are Bullish on These Healthcare Stocks: Rezolute (RZLT), Relay Therapeutics (RLAY) - The Globe and Mail

Jun 03, 2026

Relay Therapeutics Hits New 52-Week High of $17.46, Up 108.5% - MarketsMojo

Jun 03, 2026

Jun 02, 2026

JonesTrading Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $20 - Moomoo

Jun 02, 2026

Relay Therapeutics stock hits 52-week high at 17.33 USD By Investing.com - Investing.com Canada

Jun 02, 2026

RLAY stock declines pre-market after $175M offering — despite fresh bullish calls on Relay's zovegalisib - MSN

Jun 02, 2026

Relay Therapeutics Shares Surge 20% on ASCO Momentum for Zovegalisib Breast Cancer Program - International Business Times Australia

Jun 02, 2026

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June - 富途牛牛

May 29, 2026

Sector Update: Healthcare - Moomoo

May 29, 2026

May 28, 2026

Relay Therapeutics Shares Reclaim Offer Price as Traders Eye June - Bez Kabli

May 28, 2026

Relay Therapeutics (RLAY) price target increased by 14.03% to 21.42 - MSN

May 28, 2026

May 27, 2026

Relay Therapeutics to present at two major healthcare investor conferences in June 2026 - Pluang

May 27, 2026

Relay Therapeutics leaders to join two June healthcare conferences - Stock Titan

May 27, 2026

May 26, 2026

Why Relay Therapeutics stock popped on Wednesday - MSN

May 26, 2026

RLAY Maintained by Guggenheim -- Price Target Raised to $26 - GuruFocus

May 26, 2026

RLAY Maintained by HC Wainwright & Co. -- Price Target Raised to $28 - GuruFocus

May 26, 2026

H.C. Wainwright raises Relay Therapeutics stock price target to $28 on trial data By Investing.com - Investing.com South Africa

May 26, 2026

Guggenheim raises Relay Therapeutics stock price target on drug profile By Investing.com - Investing.com Australia

May 26, 2026

H.C. Wainwright raises Relay Therapeutics stock price target to $28 on trial data - Investing.com Australia

May 26, 2026

Guggenheim raises Relay Therapeutics stock price target on drug profile - Investing.com

May 26, 2026

Guggenheim Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $26 - Moomoo

May 26, 2026

H.C. Wainwright Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $28 - Moomoo

May 26, 2026

Relay Therapeutics shares jump after positive vascular anomalies trial results (RLAY) - MSN

May 26, 2026

May 24, 2026

Relay rises on mid-stage trial data for lead asset in vascular anomalies - MSN

May 24, 2026

RLAY Stock Declines Pre-Market After $175M Offering — Despite Fresh Bullish Calls On Relay's Zovegalisib - Stocktwits

May 24, 2026

May 22, 2026